medigraphic.com

2009, Number 4

<< Back Next >>

Cir Cir 2009; 77 (4)

Alteraciones en los señalamientos intracelulares en el cáncer

Valdespino-Gómez VM, Valdespino-Castillo VE, Márquez-Holmberg M

Language: Spanish
References: 29
Page: 329-339
PDF size: 118.46 Kb.


ABSTRACT

Transitions from normal cell to neoplastic malignant cell type require multiple alterations in cell signalling pathways. Transduction and transmission of these signalling pathways are dependent on integrated molecular circuits. A paramount aspect in cancer development is the concept that the cell loses its ability to detect and respond to extracellular signals and frequently develops autocrine signals for overcoming normal physiological controls. Therefore, we analyzed the current concepts of general principles in physiological and some oncogenic cell signalling pathway patterns. We carried out a documentary review of 29 scientific items in which we identified intracellular signalling pathway systems in each cell so complex due to the high number of participants and the multiple differences among specific cell types. The knowledge and identification of general principles regarding the whole physiological cell signaling pathway patterns help us to understand the oncogenic signaling pathways. Identification of these pathways in any tumor can be used as prognosis or predictor biomarkers in the patient’s outcome or as target in clinical therapeutic trials.


REFERENCES

  1. Khalil IG, Hill C. Systems biology for cancer. Curr Opin Oncol 2005;17: 44-48.

  2. Cho WCS. Latest discoveries and trend in translational cancer research: highlights of the 2008 Annual Meeting of the American Association for Cancer Research. Tec Cancer Res Treat 2008;7:269-277.

  3. Li Q-X, Yu DH, Liu G, Ke N, McKelvy J, Wong-Staal F. Selective anticancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ 2008;15:1197-1210.

  4. Pouyssegur J, Dayan F, Mazure N. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441:437-443.

  5. Cantley L, Carpenter CL. Cell Signaling. In: DeVita VT Jr, Lawrence TS, Rosenberg SA, eds. Cancer. Priciples & Practice of Oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008. pp. 67-77.

  6. Ihle JN. Señalización intracelular. En: Abeloff MD, Armitage JO, Niderhuber JE, Kastan MB, McKenna WG, editores. Oncología Clínica. Madrid: Elsevier, Churchill, Livingstone; 2005. pp. 19-45.

  7. Berg JM, Tymoczko JL, Stryer L. Bioquímica. Sexta edición. Barcelona: Editorial Reverte; 2008. pp. 381-407.

  8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.

  9. Shafer R, Schramme A, Tchernitsa OI, Sers C. Oncogenic signaling pathways and deregulated target genes. Rec Res Cancer Res 2007;176:7-19.

  10. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 4th ed. New York: Garland Science; 2002. pp. 831-906.

  11. Figeys D. Mapping the human protein interactome. Cell Res 2008;18: 716-724.

  12. Valdespino GVM, Valdespino CVE. Terapia molecular en pacientes que no responden a los tratamientos convencionales. Gac Med Mex 2008;144:333-344.

  13. Lin J, Arlinghaus R. Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene 2008;27:4385-4391.

  14. Wang X, Jiang X. PTEN: a default gate-keeping tumor suppressor with a versatile tail. Cell Res 2008;18:807-816.

  15. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006;441:424-430.

  16. Valdespino V, Valdespino Castillo P. Mecanismos epigenéticos celulares y sus alteraciones en cáncer. Gamo 2008;7:80-92.

  17. Lewin B. Genes IX. Boston: Jones and Bartlett Publishers; 2008.

  18. Libermann TA, Zerbini LF. Targeting transcription factors for cancer gene therapy. Curr Gene Ther 2006;6:17-33.

  19. Lesiak K, Sztiller-Sikorska M, Czyz M. Transcription factors in the development and progression of melanoma. Postepy Hig Med Dosw 2007;61:576-595.

  20. O’Neil J, Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogen 2007;26:6838-6849.

  21. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes an their pathways: a rationale for cancer therapy. Biochim Biophys Acta 2008;1786:87-104.

  22. Christofori G. New signals from the invasive front. Nature 2006;441:444-450.

  23. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-436.

  24. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev Immunol 2006;6: 715-727.

  25. Van’t Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452:564-570.

  26. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-728.

  27. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trail. Future Oncol 2008;4:603-610.

  28. Cardoso F, Van’t Veer LJ, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26:729-735.

  29. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph node in an independent validation study. Breast Cancer Res Treat 2008;Jul 27 [Epub ahead of print].




2020     |     www.medigraphic.com